个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Overall survival with camrelizumab plus famitinib versus camrelizumab alone and investigator's choice of chemotherapy for recurrent or metastatic cervical cancer

| 认领 | 导出 |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE

作者：
Wu, Xiaohua[1] * ; Xia, Lingfang[1] ; Zhang, Keqiang[2] ; Tang, Ying[3] ; Zhang, Guonan[4] ; Wang, Danbo[5] ; Lou, Hanmei[6] ; Liu, Naifu[7] ; Zhang, Hongping[8,9] ; Chen, Hongwei[10] ; Wang, Ke[11] ; Wei, Shuqing[12] ; Wang, Li[13,14] ; Gao, Kun[15] ; Li, Guiling[16] ; Zhang, Huifeng[17] ; Hu, Yuanjing[18] ; Zhou, Xianfeng[19] ; Wang, Yuting[19] ; Wang, Quanren[19] ;
机构： [1]Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China [2]Hunan Canc Hosp, Changsha, Peoples R China [3]Chongqing Univ Canc Hosp, Chongqing, Peoples R China [4]Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Chengdu, Peoples R China [5]Liaoning Canc Hosp & Inst, Shenyang, Peoples R China [6]Zhejiang Canc Hosp, Hangzhou, Peoples R China [7]Shandong Canc Hosp & Inst, Jinan, Shandong, Peoples R China [8]Kunming Med Univ, Yunnan Canc Hosp, Kunming, Yunnan, Peoples R China [9]Kunming Med Univ, Affiliated Hosp 3, Kunming, Yunnan, Peoples R China [10]Xi An Jiao Tong Univ, Affiliated Hosp 1, Xian, Peoples R China [11]Tianjin Med Univ Canc Inst & Hosp, Tianiin, Peoples R China [12]Shanxi Canc Hosp, Taiyuan, Peoples R China [13]Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou, Peoples R China [14]Henan Canc Hosp, Zhengzhou, Peoples R China [15]Guangxi Med Univ Canc Hosp, Nanning, Peoples R China [16]Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Wuhan, Peoples R China [17]Hubei Canc Hosp, Wuhan, Peoples R China [18]Tianjin Cent Hosp Gynecol Obstet, Tianjin, Peoples R China [19]Jiangsu Hengrui Pharmaceut Co Ltd, Shanghai, Peoples R China
出处：
ISSN：

摘要：
Objectives In the randomized, double-blind, placebo-controlled phase III NORA trial (NCT03705156) among patients with platinum-sensitive recurrent ovarian cancer (PSROC), niraparib maintenance therapy using an individualized starting dose (ISD) demonstrated a significant improvement in progression-free survival (PFS) at the primary analysis and a favorable trend in overall survival (OS) at an interim analysis, irrespective of germline BRCA mutation (gBRCAm) status. In contrast, an inconsistent OS trend was observed among patients without gBRCAm across similar trials of poly (ADP-ribose) polymerase inhibitors (PARPis) in the same setting. This analysis aimed to present the final data on OS as well as other secondary and exploratory endpoints of NORA.

语种：
外文
被引次数：
WOS：
中科院(CAS)分区：
出版当年[2024]版：
无
最新[2023]版：
大类 | 2 区 医学
小类 | 1 区 妇产科学 2 区 肿瘤学
JCR分区：
出版当年[2024]版：
无
最新[2023]版：
Q1 OBSTETRICS & GYNECOLOGY Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2023版]

第一作者：
第一作者机构： [1]Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
推荐引用方式(GB/T 7714)：
Wu Xiaohua,Xia Lingfang,Zhang Keqiang,et al.Overall survival with camrelizumab plus famitinib versus camrelizumab alone and investigator's choice of chemotherapy for recurrent or metastatic cervical cancer[J].GYNECOLOGIC ONCOLOGY.2024,190:S23-S24.
APA：
Wu, Xiaohua,Xia, Lingfang,Zhang, Keqiang,Tang, Ying,Zhang, Guonan...&Wang, Quanren.(2024).Overall survival with camrelizumab plus famitinib versus camrelizumab alone and investigator's choice of chemotherapy for recurrent or metastatic cervical cancer.GYNECOLOGIC ONCOLOGY,190,
MLA：
Wu, Xiaohua,et al."Overall survival with camrelizumab plus famitinib versus camrelizumab alone and investigator's choice of chemotherapy for recurrent or metastatic cervical cancer".GYNECOLOGIC ONCOLOGY 190.(2024):S23-S24

资源点击量：53178 今日访问量：0 总访问量：4588 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号